College of Medicine and Health, University of Exeter Medical School, Exeter, UK
College of Medicine and Health, University of Exeter, Exeter, UK.
J Med Genet. 2023 Apr;60(4):391-396. doi: 10.1136/jmg-2022-108523. Epub 2022 Aug 17.
Fabry disease is an X-linked lysosomal storage disorder resulting from deficiency of the alpha-galactosidase A enzyme leading to accumulation of globotriaosylceramide in multiple organ sites with prominent cardiovascular and renal involvement. Global prevalence estimates of Fabry disease based on clinical ascertainment range from 1 in 40 000 to 1 in 170 000. We aimed to determine the prevalence of Fabry disease-causing variants in UK Biobank.
We sought gene variants in exome sequencing data from 200 643 individuals from UK Biobank. We used ACMG/AMP guidelines (American College of Medical Genetics/Association for Molecular Pathology) to classify pathogenicity and compared baseline biomarker data, hospital ICD-10 (International Classification of Diseases version-10) codes, general practitioner records and self-reported health data with those without pathogenic variants.
We identified 81 coding variants. We identified eight likely pathogenic variants on the basis of being rare (<1/10 000 individuals) and either previously reported to cause Fabry disease, or being protein-truncating variants. Thirty-six individuals carried one of these variants. In the UK Biobank, the prevalence of likely pathogenic Fabry disease-causing variants is 1/5732 for late-onset disease-causing variants and 1/200 643 for variants causing classic Fabry disease.
Fabry disease-causing variants are more prevalent in an unselected population sample than the reported prevalence of Fabry disease. These are overwhelmingly variants associated with later onset. It is possible the prevalence of later-onset Fabry disease exceeds current estimates.
法布瑞病是一种 X 连锁溶酶体贮积病,由α-半乳糖苷酶 A 缺乏引起,导致糖鞘脂在多个器官部位堆积,主要累及心血管和肾脏。基于临床确诊的法布瑞病全球患病率估计值为每 40000 至 170000 人中有 1 例。我们旨在确定英国生物银行中法布瑞病致病变异的患病率。
我们在英国生物银行的 200643 名个体的外显子组测序数据中寻找基因变异。我们使用 ACMG/AMP 指南(美国医学遗传学学院/分子病理学协会)对致病性进行分类,并将基线生物标志物数据、医院 ICD-10(国际疾病分类第 10 版)代码、全科医生记录和自我报告的健康数据与无致病性变异的个体进行比较。
我们确定了 81 个编码变异。我们根据罕见性(<1/10000 个体)和是否先前报道过引起法布瑞病或是否为蛋白截断变异,将八种可能的致病性变异归类为致病性变异。36 名个体携带其中一种变异。在英国生物银行中,晚发型法布瑞病致病变异的患病率为每 5732 例中 1 例,经典法布瑞病致病变异的患病率为每 200643 例中 1 例。
在未选择的人群样本中,法布瑞病致病变异的患病率高于报道的法布瑞病患病率。这些变异绝大多数与晚发型疾病相关。晚发型法布瑞病的患病率可能超过目前的估计。